Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)

 Volver  Ver
Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)
 POSTER   09/2020
 Download  Ver

Para obtener más información sobre esta publicación, por favor envíe una solicitud de información médica.

Rating

Rate this publication

Publicaciones relacionadas

Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
Tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for locally advanced/metastatic nonsquamous NSCLC
Tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for locally advanced/metastatic nonsquamous NSCLC
 Volver